Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients - Summary - MDSpire
Advertisement
Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients
To evaluate the degree and durability of anti-spike protein receptor binding domain (anti-S RBD) and neutralizing antibody (NAb) response to SARS-CoV-2 vaccine in hematopoietic cell transplant (HCT) recipients, highlighting the importance of understanding vaccine effectiveness in this vulnerable population.
Key Findings:
Proportion of patients with anti-S RBD ≥ 100 U/ml increased from 13.5% before first dose to 90.6% one month after the third dose, indicating a robust response to vaccination.
Rate of seropositivity (anti-S RBD ≥ 0.8 U/ml) rose from 40.5% before first dose to 98.1% after the third dose, underscoring the effectiveness of multiple doses.
Mean percent neutralization increased significantly after vaccination, reaching 89.4% one month after the third dose, suggesting strong neutralizing capacity.
Younger patients (≤50 years) and auto-HCT recipients had higher GMTs compared to older patients and allo-HCT recipients, indicating demographic factors influence vaccine response.
Interpretation:
The study indicates that HCT recipients exhibit a significant humoral response to SARS-CoV-2 vaccination, with increased antibody levels and neutralization capacity after receiving multiple doses, emphasizing the need for tailored vaccination strategies in this group.
Limitations:
Study population may not fully represent all HCT recipients due to inclusion criteria, which could limit generalizability.
Limited follow-up duration for assessing long-term immunity, which may affect understanding of sustained protection.
Conclusion:
HCT recipients show improved antibody responses with multiple doses of SARS-CoV-2 vaccines, highlighting the critical importance of vaccination in this vulnerable population to mitigate COVID-19 risks.
by Qamar J. Khan, Cory R. Bivona, Ben Liu, Maggie Nelson, Grace A. Martin, Muhammad Umair Mushtaq, Priyanka Sharma, Natalie R. Streeter, Marc Hoffmann, Gary C. Doolittle, Cuncong Zhong, Laura Mitchell, Kevin H. Li, Ziyan Y. Pessetto, Arnab Ghosh, Harsh B. Pathak, Jun Zhang, Andrew K. Godwin, Joseph P. McGuirk
